Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summary.
作者信息
Saad Fred, Hussain Maha H A, Tombal Bertrand, Fizazi Karim, Mastris Ken, Flannery Thomas, Smith Matthew R
机构信息
aUniversity of Montreal Hospital Center, Montreal, Canada.
bFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.
出版信息
Future Oncol. 2025 Apr;21(10):1157-1170. doi: 10.1080/14796694.2025.2476929. Epub 2025 Mar 25.
Abstract
摘要
相似文献
1
Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summary.达洛鲁胺治疗转移性激素敏感性前列腺癌的前列腺特异性抗原（PSA）反应及其对ARASENS试验治疗结果的影响：通俗易懂的总结
Future Oncol. 2025 Apr;21(10):1157-1170. doi: 10.1080/14796694.2025.2476929. Epub 2025 Mar 25.
2
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.达罗他胺与转移性、激素敏感性前列腺癌的生存：一项 ARASENS 试验的患者和护理人员视角以及通俗易懂的总结。
Future Oncol. 2022 Jul;18(21):2585-2597. doi: 10.2217/fon-2022-0433. Epub 2022 Jun 3.
3
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.达罗他胺联合雄激素剥夺治疗和多西他赛治疗，深度持久的前列腺特异性抗原应答，并与高或低容量转移性激素敏感性前列腺癌患者的临床结局相关：随机 3 期 ARASENS 研究分析。
Eur Urol. 2024 Oct;86(4):329-339. doi: 10.1016/j.eururo.2024.03.036. Epub 2024 Apr 21.
4
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.达拉非尼联合雄激素剥夺治疗和多西他赛在随机 ARASENS 试验中黑种人患者中的疗效和安全性。
Oncologist. 2024 Mar 4;29(3):235-243. doi: 10.1093/oncolo/oyad254.
5
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.三药联合或两药联合治疗转移性激素敏感型前列腺癌：按疾病负荷分层的更新网络荟萃分析。
Eur Urol Focus. 2023 Sep;9(5):838-842. doi: 10.1016/j.euf.2023.03.024. Epub 2023 Apr 11.
6
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.达罗他胺：用于治疗转移性去势敏感性前列腺癌的药物。
Target Oncol. 2023 Sep;18(5):793-800. doi: 10.1007/s11523-023-00984-4. Epub 2023 Aug 5.
7
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients.达罗他胺联合雄激素剥夺疗法：ARASEC与历史临床试验患者的倾向评分匹配
Future Oncol. 2025 May;21(11):1365-1375. doi: 10.1080/14796694.2025.2482360. Epub 2025 Apr 1.
8
[Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].雄激素剥夺疗法联合化疗±雄激素受体靶向药物治疗转移性激素敏感性前列腺癌
Urologie. 2023 Apr;62(4):360-368. doi: 10.1007/s00120-023-02029-0. Epub 2023 Feb 10.
9
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.达罗他胺治疗日本转移性激素敏感性前列腺癌患者的疗效：III 期 ARASENS 亚组分析。
Cancer Med. 2024 Nov;13(21):e70029. doi: 10.1002/cam4.70029.
10
Real-world retrospective study of prostate-specific antigen and safety assessment with darolutamide plus androgen deprivation therapy for metastasis hormone-sensitive prostate cancer.达罗他胺联合雄激素剥夺疗法用于转移性激素敏感性前列腺癌的前列腺特异性抗原及安全性评估的真实世界回顾性研究
Transl Androl Urol. 2024 Mar 31;13(3):433-441. doi: 10.21037/tau-24-96. Epub 2024 Mar 25.
Zotero 插件